Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK4524101 · 1 trial · 1 indication
ORR is the percentage of participants with an Investigator-assessed confirmed complete response and confirmed partial response to treatment, as assessed by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1
| Arm | Type | Description |
|---|---|---|
| Part 1 - GSK4524101 Monotherapy | EXPERIMENTAL | - |
| Part 1 - GSK4524101 plus Niraparib | EXPERIMENTAL | - |
| Part 1 - GSK4524101 Food Effect Cohort | EXPERIMENTAL | - |
| Part 2 - GSK4524101 plus Niraparib | EXPERIMENTAL | - |
| Part 2 - Niraparib | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GSK4524101 | DRUG | GSK452101 will be administered. |
| Niraparib | DRUG | Niraparib will be administered. |
Inclusion Criteria: * More than or equal to (≥)18 years of age * Eastern cooperative oncology group (ECOG) class 0-2 * Life expectancy of a minimum of 3 month * Participant has histologically diagnosed advanced or metastatic solid tumor and has exhausted all standard of care treatment options (Part...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
GSK4524101 is an investigational small molecule being developed for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently being studied in a Phase 1 clinical trial in participants with solid tumors, both alone and in combination with niraparib.
The specific molecular target of GSK4524101 has not been disclosed. It is being studied for its potential anticancer activity in solid tumors, and the ongoing clinical trial is evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy.
GSK4524101 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting a Phase 1 clinical trial to investigate the drug's safety and preliminary anticancer activity in participants with solid tumors.
GSK4524101 is in Phase 1 of clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety, tolerability, and preliminary efficacy in humans.
GSK4524101 is being studied in a Phase 1 clinical trial with the identifier NCT06077877. The trial is investigating the safety, tolerability, pharmacokinetics, and preliminary anticancer activity of GSK4524101 alone or with niraparib in participants with solid tumors. The trial is active but not recruiting, with an enrollment of 42 participants.
No, GSK4524101 is not the same as niraparib. GSK4524101 is the investigational drug being studied, while niraparib is a separate medication that is being used in combination with GSK4524101 in the clinical trial. The trial is evaluating the effects of GSK4524101 both alone and in combination with niraparib.